samedan logo
 
 
 
spacer
home > ebr > summer 2004 > maximise the return on ethics consultations by minimising deficit thinking
PUBLICATIONS
European Biopharmaceutical Review

Maximise the Return on Ethics Consultations by Minimising Deficit Thinking

It has become commonplace for representatives from industry to be involved in discussions about the broader social issues surrounding science and technology. For many people this may involve requests to participate in public engagement exercises, ethical consultations and policy-making procedures. These exercises are designed to create transparent and engaged relationships between science, industry and the public. They are imagined to hold potential commercial benefits that include the promotion of novel technologies in society, as well as the fostering of public confidence in industry. However, achieving these gains is contingent upon confronting the complex relationship between science and society. In this article, we will examine how deeply embedded assumptions about knowledge and expertise may curtail the potential to achieve positive outcomes through participation and engagement.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Andrew Smart, Sociology Research Officer for the Oxford Genetics Knowledge Park and Dr Kevin E Jones, Senior Research Associate with the Programme on Understanding Risk at Brunel University

Dr Andrew Smart is the Sociology Research Officer for the Oxford Genetics Knowledge Park, based at The Ethox Centre, University of Oxford. His work is focused on the social aspects of human genetics research. He is currently exploring the social implications of translating genetics research into clinical practice. In his previous research, he has examined the commercial and clinical development of pharmacogenetics, and mass media coverage of the ethical, legal and social implications of human genetics.


Dr Kevin E Jones is a Senior Research Associate with the Programme on Understanding Risk at Brunel University. His current research investigates the relationship between social exclusion and public perceptions of risk and science. Kevin has written widely on a variety of scientific controversies, including the debate over agricultural biotechnology, the management of BSE in the UK and the introduction of growth hormones in the North American dairy industry.

spacer
Dr Andrew Smart
spacer
spacer
spacer
Dr Kevin E Jones
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Envirotainer praises industry collaboration as it handles billionth vaccine

Stockholm, December 22, 2021: Envirotainer, the global market leader in secure cold-chain solutions for air transportation of pharmaceuticals, is calling for continued collaboration between pharmaceutical firms and the logistics industry.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement